Trump delivered historic drops in prescription drug prices, but Congress must rein in PBM middlemen to make those savings last.

Falling prescription drug prices are driven by fierce GLP-1 market competition, not by White House policies or government portals.

The string of deals builds on the Trump administration's push to link the nation's drug prices to cheaper ones abroad.